Revolutionizing Immune Health with Breakthrough Vaccines

Leading Immunology Forward with Breakthrough Vaccines and Diagnostics

Vactech is pioneering the future of immunology by developing groundbreaking vaccines and diagnostic technologies focused on type 1 diabetes, celiac disease, and enterovirus-related conditions. Since 2001, our commitment has been clear: pursue research that delivers real-world impact, combining academic excellence with substantial commercial potential and industrial partners.

Transformative Preventive Vaccine for Type 1 Diabetes with Global Impact

Our flagship innovation—a patented preventive vaccine for type 1 diabetes—is currently advancing through clinical trials to offer solution to this rapidly growing global health issue affecting 15 million people. With projected revenues exceeding $17 billion within the first decade post-launch in the US and EU alone, this vaccine represents a transformative opportunity for investors and healthcare partners.

Proven Technology Offering Broad Protection Against Enterovirus Diseases

Built on robust international science and use of samples from unique large biobanks, our vaccine uses safe, proven technology similar to the globally successful polio vaccine. Beyond diabetes prevention, our vaccine targets several other enterovirus-related diseases, including both acute infections and chronic enterovirus-linked diseases such as cardiomyopathies and celiac disease.

Our renowned scientific founders, recognized globally in immunology and virology, have secured significant international awards and strategic partnerships.